Page last updated: 2024-12-06

thiophene-2-carboxylic acid hydrazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thiophene-2-carbohydrazide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73098
CHEMBL ID3091844
SCHEMBL ID355263
MeSH IDM0065939

Synonyms (53)

Synonym
BIDD:GT0451
nsc-120045
nsc120045
2-thiophenecarboxylic acid hydrazide
thiophene-2-carboxylic acid hydrazide
2-thienylcarboxylic acid hydrazide
2-thiophenecarbohydrazonic acid
2361-27-5
nsc-653
2-thenoylhydrazine
nsc653
2-thiophenecarboxylic acid, hydrazide
thiophene-2-carbohydrazide
2-thiophenecarboxylic acid hydrazide, >=98%
STK061684
AKOS000200290
2-thiophenecarboxylic hydrazide
sogbogbtikmgfs-uhfffaoysa-
inchi=1/c5h6n2os/c6-7-5(8)4-2-1-3-9-4/h1-3h,6h2,(h,7,8)
T1140
HMS1722A21
2-thiophene carboxylic hydrazide
thiophene-2-carboxylic hydrazide
A816801
unii-w4j3wef93n
nsc 653
einecs 219-107-0
w4j3wef93n ,
FT-0634215
PS-5271
SCHEMBL355263
CHEMBL3091844
2-thiophenecarboxylicacidhydrazide
2thiophenecarboxylic hydrazide
2-thiophene carboxylic acid hydrazide
2-thiophencarboxylic acid hydrazide
2-thiophenecarbohydrazide
thenohydrazide
W-107392
2-thiophenecarbohydrazide #
2-thienyl hydrazide
2-thenoic hydrazide
DTXSID80178271
F3146-2497
mfcd00005435
BBL104270
thiophene-2-carboxylic hydrazone
SY048333
AM9858
F10320
EN300-17658
CS-W018291
Z56974792
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1059231Antitubercular activity against Mycobacterium tuberculosis2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID1422882Binding affinity to recombinant Trypanosoma cruzi His/haemaglutinin-tagged BDF3 expressed in Escherichia coli BL21 at 100 uM by fluorescence spectra analysis2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID1059234Lipophilicity, log P of the compound2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (47.83)18.7374
1990's1 (4.35)18.2507
2000's1 (4.35)29.6817
2010's9 (39.13)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.58 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]